Full Breakdown
PARTNERS Trial Launches Amid Bundibugyo Ebola Outbreak in the DRC
7/3/2026, 10:22:27 PM
Outbreak Background and Scale
The Bundibugyo strain of Ebola, first identified in Uganda in 2007, resurfaced in May 2026 in the Democratic Republic of Congo (DRC) and Uganda. WHO reports more than 1,400 confirmed cases in the DRC with deaths ranging from 438 to 447 across sources. Uganda has reported 20 confirmed cases and two deaths, and a single case was identified in France. No approved vaccine or therapeutic exists for this strain; supportive care alone has produced roughly 190-213 recoveries.
Key Organizations and Personnel
The Platform Adaptive Randomised Trial for New and Repurposed Filovirus Treatments (PARTNERS) is sponsored by the World Health Organization and coordinated by the DRC’s Institut National de Recherche Biomédicale (INRB), Belgium’s Institute of Tropical Medicine, and the University of Oxford. Supporting partners include Africa CDC, ALIMA, Médecins Sans Frontières, and the Alliance for International Medical Action. Principal figures are WHO Director-General Dr. Tedros Adhanom Ghebreyesus, PARTNERS Trial Operations Lead Prof. Amanda Rojek (University of Oxford), INRB Director-General Prof. Jean-Jacques Muyembe-Tamfum, and WHO research adviser Dr. Vasee Moorthy.
Trial Design and Therapeutics
PARTNERS is a randomized, adaptive platform trial enrolling patients with laboratory-confirmed Bundibugyo virus disease at a single Ebola treatment center in Ituri province. Participants receive standard supportive care and are assigned to receive either the monoclonal antibody MBP-134 (Mapp Biopharma), the antiviral remdesivir (Gilead Sciences), both agents combined, or no investigational drug. Follow-up lasts at least 28 days. The design permits addition of new agents—such as maftivimab—and may require up to 1,000 enrolments before definitive efficacy conclusions.
Data and Statistics
- Confirmed DRC cases: 1,406 – 1,460 (source variation)
- Deaths in DRC: 438 – 447
- Recoveries reported: 190 – 213
- Uganda cases: 20; deaths: 2
- Africa CDC funding gap: US$ 1.4 billion (? 3 × earlier estimate)
Potential Impact
If either investigational product proves effective, WHO will seek broader access for future outbreaks. Successful results could fill the current therapeutic void for Bundibugyo Ebola and inform rapid-response strategies for other filoviruses.
Official Statements & Responses
WHO emphasized that the trial “offers real hope” and that integrating research with emergency response can generate actionable evidence within months. Africa CDC highlighted the urgent need for additional financing to sustain response activities. DRC Health Minister Dr. Samuel Kamba called the launch a “major milestone” for national public-health capacity. INRB leadership stressed that the trial embeds promising therapies within routine patient care, accelerating evidence generation.
Criticism & Funding Gaps
Africa CDC Director-General Jean Kaseya warned that the response requires US$ 1.4 billion—far exceeding prior estimates—underscoring a substantial funding shortfall. Community resistance, including attacks on treatment facilities, raises concerns about trial security and patient enrollment.
On-the-Ground Conditions
The trial operates from a single center in Ituri province, the outbreak’s epicenter, where displaced populations exceed 1.3 million and contact-tracing rates are about 45 percent. Security incidents, such as the arson of isolation tents, illustrate persistent mistrust of health interventions.
Conflicting Reports & Gaps
Sources differ on confirmed case counts (1,406 vs. 1,460) and death totals (438 vs. 447). Recovery numbers also vary. No independent verification of enrolment beyond the first patient has been published.
Verbatim Quotes
- “The clinical trial of two therapeutics began, with the enrolment of the first patient.” — Dr. Tedros Adhanom Ghebreyesus, WHO Director-General
- “We urgently need treatments that can help people affected by Bundibugyo virus disease. One of the key lessons from recent outbreaks is that research needs to happen alongside the response, not after it,” — Prof. Amanda Rojek, PARTNERS Trial Operations Lead
- “So we shouldn't expect that this is going to be over in weeks. It will take some months. It could go even into next year. It could be that we need over a thousand patients enrolled in the trial until we get a definitive answer. That will be earlier if there's a very high efficacy from the trial.” — Dr. Vasee Moorthy, WHO Research Adviser
- “The data on MBP-134 for Bundibugyo Ebola raise expectations for its therapeutic benefit,” — Prof. Thomas Geisbert, University of Texas
- “By integrating this trial into clinical care, we are giving patients access to promising investigational treatments while generating the evidence needed to improve care for current and future outbreaks,” — Prof. Jean-Jacques Muyembe-Tamfum, INRB Director-General
- “The PARTNERS trial, established with national authorities and scientific partners in record time, offers real hope that we can deliver concrete results for—and with—the communities at the heart of the outbreak,” — Dr. Tedros Ghebreyesus
What’s Next
WHO plans to expand enrollment to additional sites when security permits, to evaluate prophylactic oral antiviral obeldesivir for contacts, and to consider adding maftivimab. Trial results are expected later this year or early next year, guiding potential licensure and scale-up of effective therapies.
